Hostname: page-component-7857688df4-xdcjr Total loading time: 0 Render date: 2025-11-16T06:37:36.231Z Has data issue: false hasContentIssue false
  • English
  • Français

Contaminated Commercial Charcoal as a Source of fungi in the Respiratory Tract

Published online by Cambridge University Press:  21 June 2016

David L. George ,
Rima McLeod  and
Robert A. Weinstein
David L. George
Affiliation:
Division of Infectious Diseases, Department of Medicine, Michael Reese Hospital and Medical Center, Chicago, Illinois
Rima McLeod
Affiliation:
Division of Infectious Diseases, Department of Medicine, Michael Reese Hospital and Medical Center, Chicago, Illinois
Robert A. Weinstein*
Affiliation:
Division of Infectious Diseases, Department of Medicine, Michael Reese Hospital and Medical Center, Chicago, Illinois
*
Department of Medicine, Michael Reese Hospital and Medical Center, Lakeshore Dr. at 31st St., Chicago, IL 60616
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To investigate the possibility that contaminated commercial activated charcoal may serve as a source for fungal colonization or infection of the lower respiratory tract.

Design:

The clinical course of a patient who aspirated commercial activated charcoal was reviewed. Fungal cultures were performed for 2 samples of an activated charcoal in sorbitol product from separate lots produced by a single manufacturer. Details of the manufacturing process were obtained from a representative of the manufacturer.

Setting:

An intensive care unit in a large community teaching hospital.

Patients:

A single patient with steroid-treated lung disease who developed a fatal pulmonary illness after aspirating a commercial activated charcoal product.

Results:

After aspirating the charcoal product, the patient developed respiratory tract colonization and possible infection with Aspergillus niger, Paecilomyces variotii, and Penicillium species. Similar fungal species were isolated from cultures of samples obtained from two separate lots of the same commercial activated charcoal product. Several opportunities for contamination during the manufacturing process were identified.

Conclusions:

Physicians caring for immuno-compromised patients should be aware that commercial activated charcoal products can be a source of fungal respiratory tract colonization that may mimic or cause pneumonia.

Information

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 12 , Issue 12 , December 1991 , pp. 732 - 734
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1991 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

REFERENCES

1. Menzies, DG, Busuttil, A, Prescott, LF. Fatal pulmonary aspiration of oral activated charcoal. Br Med J. 1988;297:459–60.Google Scholar
2. Harsch, HH. Aspiration of activated charcoal. N Engl J Med. 1986;314:318.Google Scholar
3. Pollack, MM, Dunbar, BS, Holbrook, PR, Fields, AI. Aspiration of activated charcoal and gastric contents. Ann Emerg Med. 1981;10:528–529.Google Scholar
4. Sessler, CN. Poor tolerance of oral activated charcoal with theophylline overdose, Am J Emerg Med. 1987;5:492–495.Google Scholar
5. Justiniani, FR, Hippalgaonkar, R, Martinez, LO. Charcoal-containing empyema complicating treatment for overdose. Chest. 1985;87:404–405.Google Scholar
6. Rau, NR, Nagaraj, MV, Prakash, PS, Nelli, P. Fatal pulmonary aspiration of oral activated charcoal. Br Med J. 1988;297:918–919.Google Scholar
7. Dunbar, BS, Pollack, MM, Shahvari, MBG. Cardiorespiratory changes after charcoal aspiration. Crit Cure Med. 1981;9:221.Google Scholar
8. Yu, VL, Muder, RR, Poorsattar, A. Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis: results from a three-year prospective study. Am J Med. 1986;81:249–254.Google Scholar
9. Huang, SN, Harris, LS. Acute disseminated penicilliosis. Am J Clin Pathol. 1963;39:167–174.Google Scholar
10. Dharmasena, FMC, Davies, GSR, Catovsky, D. Paecilomyces varioti pneumonia complicating hairy cell leukemia. Br Med J. 1985;290:967–968.Google Scholar
11. Weiland, D, Ferguson, RM, Peterson, PK, Snover, DC, Simmons, RL, Najarian, JS. Aspergillosis in 25 renal transplant recipients: epidemiology, clinical presentation, diagnosis, and management. Ann Surg. 1983;198:622–629.Google Scholar
12. George, PJM, Boffa, PBJ, Naylor, CPE, Higgenbottom, TW. Necrotising pulmonary aspergillosis complicating the management of patients with obstructive airways disease. Thorax. 1983;38:478–480.Google Scholar
13. Lake, KB, Browne, PM, Van Dyke, JJ, Ayers, L. Fatal disseminated aspergillosis in an asthmatic patient treated with corticosteroids. Chest. 1981;83:138–139.Google Scholar
14. Amitai, Y, Yeung, AC, Moye, J, Lovejoy, FH. Repetitive oral activated charcoal and control of emesis in severe theophylline toxicity. Ann Intern Med. 1986;105:386–387.Google Scholar
15. Keller, F, Hennemann, H, Barz, R. Adsorption of Candida albicans from blood of infected rats by coated charcoal: a model for the diagnosis of septicaemia. Mykosen. 1982;25:64–72.Google Scholar
16. Desai, BM, Modi, W, Shah, VK. Studies on polyol metabolism in Aspergillus niger. I. Nutritional requirements of a strain of Aspergillus niger cultivated on sorbitol as a sole source of carbon. Arch Microbiol. 1969;67:6–11.Google Scholar